KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Investing Activities: 2011-2025

Historic Cash from Investing Activities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $48.7 million.

  • Supernus Pharmaceuticals' Cash from Investing Activities rose 163.25% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.8 million, marking a year-over-year increase of 117.59%. This contributed to the annual value of -$189.9 million for FY2024, which is 170.65% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Cash from Investing Activities stood at $48.7 million, which was up 259.13% from -$30.6 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash from Investing Activities peaked at $239.8 million during Q1 2023, and registered a low of -$82.2 million during Q3 2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$12.6 million (2024), whereas its average is $12.2 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 1,341.65% in 2022, then soared by 484.57% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at $76.1 million in 2021, then crashed by 164.05% to -$48.8 million in 2022, then slumped by 35.30% to -$66.0 million in 2023, then surged by 80.85% to -$12.6 million in 2024, then soared by 163.25% to $48.7 million in 2025.
  • Its Cash from Investing Activities stands at $48.7 million for Q3 2025, versus -$30.6 million for Q2 2025 and $37.3 million for Q1 2025.